Cargando…

Hospital versus home treatment of respiratory exacerbations in cystic fibrosis

BACKGROUND: Treatment of respiratory exacerbations in Cystic Fibrosis (CF) is important in slowing disease progression. The treatment may be given either at home or at the hospital. The aim of our study was to compare both treatment settings. MATERIAL/METHODS: We retrospectively analyzed data of 139...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavie, Moran, Vilozni, Daphna, Sokol, Gil, Somech, Raz, Szeinberg, Amir, Efrati, Ori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628126/
https://www.ncbi.nlm.nih.gov/pubmed/22129901
http://dx.doi.org/10.12659/MSM.882129
_version_ 1782266380712673280
author Lavie, Moran
Vilozni, Daphna
Sokol, Gil
Somech, Raz
Szeinberg, Amir
Efrati, Ori
author_facet Lavie, Moran
Vilozni, Daphna
Sokol, Gil
Somech, Raz
Szeinberg, Amir
Efrati, Ori
author_sort Lavie, Moran
collection PubMed
description BACKGROUND: Treatment of respiratory exacerbations in Cystic Fibrosis (CF) is important in slowing disease progression. The treatment may be given either at home or at the hospital. The aim of our study was to compare both treatment settings. MATERIAL/METHODS: We retrospectively analyzed data of 139 treatments in 54 CF patients (age range12–47 y) treated for respiratory exacerbations at the hospital (n=84) and/or at home (n=55). Primary outcomes were improvement in pulmonary function tests (PFTs), weight gain and duration of treatment in relation to treatment setting. Secondary outcomes were these same parameters, but in relation to different clinical preconditions and CF-related complications. RESULTS: Mean improvement in FEV1 (% predicted) was similar between the hospital and home treatments (14.3±34.4% vs. 14.3±20.2%, respectively; NS), yet treatment duration was significantly shorter at the hospital (9.7±6.7 vs. 16.3±9.1 days, respectively; P<0.02), especially for patients colonized with Pseudomonas aeruginosa (11.1±5.5 vs. 18.0±11.0 days, respectively; p<0.01). At the hospital, a subgroup of patients with CF-related complications improved their FEV1 significantly more than those at home (13.1±19.4% vs. 1.9±14.9%, respectively; P<0.02), particularly patients with CF-related diabetes mellitus (CFRDM) (11.4±18.7% vs. 1.7±14.6%, respectively; P<0.05). Patients tended to gain more weight at the hospital compared to home treatment (1.36±4.6 kg and 0.49±3.6 kg respectively; P=0.06). CONCLUSIONS: Hospital treatment for acute respiratory exacerbations in CF may be superior to home treatment, as indicated by a shorter duration of hospitalization, better improvement in FEV1 in patients with CF-related complications, CFRDM in particular and a trend toward better weight gain.
format Online
Article
Text
id pubmed-3628126
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-36281262013-04-24 Hospital versus home treatment of respiratory exacerbations in cystic fibrosis Lavie, Moran Vilozni, Daphna Sokol, Gil Somech, Raz Szeinberg, Amir Efrati, Ori Med Sci Monit Clinical Research BACKGROUND: Treatment of respiratory exacerbations in Cystic Fibrosis (CF) is important in slowing disease progression. The treatment may be given either at home or at the hospital. The aim of our study was to compare both treatment settings. MATERIAL/METHODS: We retrospectively analyzed data of 139 treatments in 54 CF patients (age range12–47 y) treated for respiratory exacerbations at the hospital (n=84) and/or at home (n=55). Primary outcomes were improvement in pulmonary function tests (PFTs), weight gain and duration of treatment in relation to treatment setting. Secondary outcomes were these same parameters, but in relation to different clinical preconditions and CF-related complications. RESULTS: Mean improvement in FEV1 (% predicted) was similar between the hospital and home treatments (14.3±34.4% vs. 14.3±20.2%, respectively; NS), yet treatment duration was significantly shorter at the hospital (9.7±6.7 vs. 16.3±9.1 days, respectively; P<0.02), especially for patients colonized with Pseudomonas aeruginosa (11.1±5.5 vs. 18.0±11.0 days, respectively; p<0.01). At the hospital, a subgroup of patients with CF-related complications improved their FEV1 significantly more than those at home (13.1±19.4% vs. 1.9±14.9%, respectively; P<0.02), particularly patients with CF-related diabetes mellitus (CFRDM) (11.4±18.7% vs. 1.7±14.6%, respectively; P<0.05). Patients tended to gain more weight at the hospital compared to home treatment (1.36±4.6 kg and 0.49±3.6 kg respectively; P=0.06). CONCLUSIONS: Hospital treatment for acute respiratory exacerbations in CF may be superior to home treatment, as indicated by a shorter duration of hospitalization, better improvement in FEV1 in patients with CF-related complications, CFRDM in particular and a trend toward better weight gain. International Scientific Literature, Inc. 2011-12-01 /pmc/articles/PMC3628126/ /pubmed/22129901 http://dx.doi.org/10.12659/MSM.882129 Text en © Med Sci Monit, 2011 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
spellingShingle Clinical Research
Lavie, Moran
Vilozni, Daphna
Sokol, Gil
Somech, Raz
Szeinberg, Amir
Efrati, Ori
Hospital versus home treatment of respiratory exacerbations in cystic fibrosis
title Hospital versus home treatment of respiratory exacerbations in cystic fibrosis
title_full Hospital versus home treatment of respiratory exacerbations in cystic fibrosis
title_fullStr Hospital versus home treatment of respiratory exacerbations in cystic fibrosis
title_full_unstemmed Hospital versus home treatment of respiratory exacerbations in cystic fibrosis
title_short Hospital versus home treatment of respiratory exacerbations in cystic fibrosis
title_sort hospital versus home treatment of respiratory exacerbations in cystic fibrosis
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628126/
https://www.ncbi.nlm.nih.gov/pubmed/22129901
http://dx.doi.org/10.12659/MSM.882129
work_keys_str_mv AT laviemoran hospitalversushometreatmentofrespiratoryexacerbationsincysticfibrosis
AT viloznidaphna hospitalversushometreatmentofrespiratoryexacerbationsincysticfibrosis
AT sokolgil hospitalversushometreatmentofrespiratoryexacerbationsincysticfibrosis
AT somechraz hospitalversushometreatmentofrespiratoryexacerbationsincysticfibrosis
AT szeinbergamir hospitalversushometreatmentofrespiratoryexacerbationsincysticfibrosis
AT efratiori hospitalversushometreatmentofrespiratoryexacerbationsincysticfibrosis